RS60030B1 - Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma) - Google Patents
Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)Info
- Publication number
- RS60030B1 RS60030B1 RS20200276A RSP20200276A RS60030B1 RS 60030 B1 RS60030 B1 RS 60030B1 RS 20200276 A RS20200276 A RS 20200276A RS P20200276 A RSP20200276 A RS P20200276A RS 60030 B1 RS60030 B1 RS 60030B1
- Authority
- RS
- Serbia
- Prior art keywords
- bcma
- monoclonal antibodies
- antibodies against
- against human
- cell maturation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15179549 | 2015-08-03 | ||
| PCT/EP2016/068549 WO2017021450A1 (en) | 2015-08-03 | 2016-08-03 | Monoclonal antibodies against bcma |
| EP16750150.1A EP3331910B1 (en) | 2015-08-03 | 2016-08-03 | Monoclonal antibodies against human b cell maturation antigen (bcma) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60030B1 true RS60030B1 (sr) | 2020-04-30 |
Family
ID=53776451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20200276A RS60030B1 (sr) | 2015-08-03 | 2016-08-03 | Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma) |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10683369B2 (sr) |
| EP (2) | EP3331910B1 (sr) |
| JP (2) | JP6682632B2 (sr) |
| KR (1) | KR20180042271A (sr) |
| CN (1) | CN108350073B (sr) |
| AU (1) | AU2016302881B2 (sr) |
| BR (1) | BR112018001955B1 (sr) |
| CA (1) | CA2992797A1 (sr) |
| CL (3) | CL2018000281A1 (sr) |
| CO (1) | CO2018001149A2 (sr) |
| CY (1) | CY1122804T1 (sr) |
| DK (1) | DK3331910T3 (sr) |
| EA (2) | EA202092435A3 (sr) |
| EC (1) | ECSP18007905A (sr) |
| ES (1) | ES2777602T3 (sr) |
| HK (1) | HK1249114A1 (sr) |
| HR (1) | HRP20200390T1 (sr) |
| HU (1) | HUE048939T2 (sr) |
| IL (1) | IL257233B (sr) |
| LT (1) | LT3331910T (sr) |
| MX (2) | MX2018001398A (sr) |
| NZ (1) | NZ739252A (sr) |
| PL (1) | PL3331910T3 (sr) |
| PT (1) | PT3331910T (sr) |
| RS (1) | RS60030B1 (sr) |
| SA (1) | SA518390854B1 (sr) |
| SG (1) | SG10202007177XA (sr) |
| SI (1) | SI3331910T1 (sr) |
| WO (1) | WO2017021450A1 (sr) |
| ZA (1) | ZA201800435B (sr) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2014056783A1 (en) | 2012-10-08 | 2014-04-17 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
| CA2891493C (en) | 2013-02-26 | 2022-03-15 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| PE20211533A1 (es) | 2014-08-04 | 2021-08-16 | Hoffmann La Roche | Moleculas biespecificas de unon a antigeno activadoras de celulas t |
| AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
| DK3221355T3 (da) | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
| AR106201A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
| KR20180085740A (ko) | 2015-12-09 | 2018-07-27 | 에프. 호프만-라 로슈 아게 | 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체 |
| IL259588B2 (en) | 2016-01-08 | 2023-09-01 | Hoffmann La Roche | Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3 |
| SG10202007836WA (en) | 2016-02-17 | 2020-09-29 | Seattle Genetics Inc | Bcma antibodies and use of same to treat cancer and immunological disorders |
| ES2947230T3 (es) | 2016-03-22 | 2023-08-03 | Hoffmann La Roche | Moléculas biespecíficas para linfocitos T activadas por proteasa |
| JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｃｄ３に対する二重特異性抗体 |
| CN110167964B (zh) * | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111094353A (zh) | 2017-09-14 | 2020-05-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| JP2020533382A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌の組合せ治療 |
| WO2019053612A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
| EP3694871A4 (en) * | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | B-CELL MATURATION ANTIG-BINDING PROTEINS |
| CN111629749A (zh) | 2017-10-18 | 2020-09-04 | 诺华股份有限公司 | 用于选择性蛋白质降解的组合物和方法 |
| JP2021502979A (ja) | 2017-11-15 | 2021-02-04 | ノバルティス アーゲー | Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法 |
| US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| WO2019149269A1 (zh) | 2018-02-01 | 2019-08-08 | 信达生物制药(苏州)有限公司 | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 |
| AU2019218959A1 (en) | 2018-02-08 | 2020-09-03 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
| EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| JP2021514193A (ja) | 2018-02-21 | 2021-06-10 | セルジーン コーポレイション | Ｂｃｍａ結合抗体及びその使用 |
| EP3774901A1 (en) * | 2018-03-26 | 2021-02-17 | Sutro Biopharma, Inc. | Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies |
| AU2019243665B2 (en) | 2018-03-30 | 2023-06-01 | Merus N.V. | Multivalent antibody |
| BR112020023704A2 (pt) * | 2018-05-23 | 2021-02-17 | Celgene Corporation | compostos antiproliferativos e anticorpo bispecífico contra bcma e cd3 para uso combinado |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| MA53293A (fr) * | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| CN109134665B (zh) * | 2018-08-24 | 2021-06-11 | 上海先博生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| BR112021003305A2 (pt) | 2018-08-31 | 2021-05-25 | Novartis Ag | métodos para produzir células que expressam receptor de antígeno quimérico |
| JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス，インク． | Ｄｌｌ３結合タンパク質および使用方法 |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| WO2020089437A1 (en) | 2018-10-31 | 2020-05-07 | Engmab Sàrl | Combination therapy |
| EP3874272A1 (en) | 2018-10-31 | 2021-09-08 | GlaxoSmithKline Intellectual Property Development Limited | Methods of treating cancer |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| CN109678961A (zh) * | 2019-01-15 | 2019-04-26 | 深圳市南科生物工程有限公司 | 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用 |
| EP3930763A1 (en) | 2019-02-25 | 2022-01-05 | Novartis AG | Mesoporous silica particles compositions for viral delivery |
| US20230074800A1 (en) | 2019-03-21 | 2023-03-09 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| WO2020219978A1 (en) | 2019-04-25 | 2020-10-29 | Celgene Corporation | Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies |
| CN110229232B (zh) * | 2019-06-19 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 双特异性抗体及其用途 |
| WO2021018168A1 (zh) * | 2019-07-30 | 2021-02-04 | 上海翰森生物医药科技有限公司 | 抗bcma抗体、其抗原结合片段及其医药用途 |
| BR112022002236A2 (pt) | 2019-08-06 | 2022-05-03 | Glaxosmithkline Ip Dev Ltd | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas |
| CN112574308A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| JP2022551662A (ja) * | 2019-10-10 | 2022-12-12 | 蘇州親為薬業有限公司 | Ｂｃｍａを標的とする、ヒトサルの交差反応性を有するヒト化モノクローナル抗体 |
| KR20220093141A (ko) * | 2019-11-05 | 2022-07-05 | 브리스톨-마이어스 스큅 컴퍼니 | Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3) |
| AU2020393912A1 (en) | 2019-11-26 | 2022-06-09 | Novartis Ag | Chimeric antigen receptors binding BCMA and CD19 and uses thereof |
| TW202128769A (zh) * | 2020-01-03 | 2021-08-01 | 大陸商信立泰（成都）生物技術有限公司 | 結合bcma的抗體及其用途 |
| KR20220110224A (ko) * | 2020-01-03 | 2022-08-05 | 바이오션, 인코포레이티드 | Bcma에 결합하는 항체 및 이의 용도 |
| CN111234020B (zh) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | 一种bcma结合蛋白及其制备方法和应用 |
| CN111171147B (zh) * | 2020-02-11 | 2021-07-20 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c3分子的全人源单克隆抗体及应用 |
| BR112022014646A2 (pt) * | 2020-02-12 | 2022-09-13 | Bristol Myers Squibb Co | Terapia anti-bcma em transtornos autoimunes |
| JP2023515211A (ja) | 2020-02-27 | 2023-04-12 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| MX2022010604A (es) | 2020-02-27 | 2022-09-09 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
| KR20230007384A (ko) | 2020-04-30 | 2023-01-12 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 방법 |
| IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | zbtb32 inhibitors and uses thereof |
| EP4192875A1 (en) * | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| EP4199960A2 (en) | 2020-08-21 | 2023-06-28 | Novartis AG | Compositions and methods for in vivo generation of car expressing cells |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| CN112321713B (zh) * | 2020-12-31 | 2021-05-25 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
| WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| WO2022232488A1 (en) | 2021-04-30 | 2022-11-03 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
| BR112023024804A2 (pt) | 2021-05-28 | 2024-02-15 | Glaxosmithkline Ip Dev Ltd | Terapias de combinação para tratar câncer |
| CA3227515A1 (en) | 2021-08-03 | 2023-02-09 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and stable isotope labeling peptide mapping method |
| CN116745325A (zh) * | 2021-08-16 | 2023-09-12 | 上海优替济生生物医药有限公司 | Bcma靶向抗体、嵌合抗原受体及其应用 |
| WO2023021477A1 (en) | 2021-08-20 | 2023-02-23 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
| CA3233953A1 (en) | 2021-10-05 | 2023-04-13 | Matthew Bruce | Combination therapies for treating cancer |
| WO2023144702A1 (en) | 2022-01-25 | 2023-08-03 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy for cancer |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CN1183802A (zh) | 1994-12-30 | 1998-06-03 | 行星生物技术有限公司 | 在植物中生产含有保护性蛋白质的免疫球蛋白的方法和应用 |
| GB9501079D0 (en) | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ES2176574T3 (es) | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| EP2270148A3 (en) | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| CA2438682A1 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| CA2457636C (en) | 2001-08-10 | 2012-01-03 | Aberdeen University | Antigen binding domains |
| ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| EP1314741B1 (en) | 2001-11-14 | 2007-03-07 | Affimed Therapeutics AG | Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| GB0230201D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
| ATE475708T1 (de) | 2003-01-22 | 2010-08-15 | Glycart Biotechnology Ag | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
| EP1599504B1 (en) | 2003-02-25 | 2014-12-03 | Vaccibody AS | Modified antibody |
| US20050033031A1 (en) | 2003-08-07 | 2005-02-10 | Couto Fernando Jose Rebelo Do | Methods for humanizing rabbit monoclonal antibodies |
| JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法 |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CA2567655C (en) | 2004-06-02 | 2015-06-30 | Diatech Pty Ltd | Binding moieties based on shark ignar domains |
| JP4937138B2 (ja) | 2005-01-05 | 2012-05-23 | エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| CA2619244A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| EP2395024B1 (en) | 2005-08-26 | 2018-12-19 | Roche Glycart AG | Modified antigen binding molecules with altered cell signaling activity |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| CA2648849A1 (en) | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals, Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
| US9212230B2 (en) | 2007-03-29 | 2015-12-15 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP4059964A1 (en) | 2007-04-03 | 2022-09-21 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
| JP2010524851A (ja) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
| US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| KR20100097737A (ko) | 2008-01-15 | 2010-09-03 | 에프. 호프만-라 로슈 아게 | Ｃｃｒ５에 대한 어푸코실화된 항체 및 이의 용도 |
| NO2842575T3 (sr) | 2008-03-18 | 2018-02-24 | ||
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| CA2738565C (en) | 2008-10-01 | 2023-10-10 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| PL2352763T5 (pl) | 2008-10-01 | 2023-01-30 | Amgen Research (Munich) Gmbh | Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej |
| CA3053156A1 (en) | 2008-12-03 | 2010-06-10 | Genmab A/S | Antibody variants having modifications in the constant region |
| NZ612647A (en) * | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| EP2640750A1 (en) * | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
| MX336740B (es) | 2011-03-29 | 2016-01-29 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| EP4338754A2 (en) * | 2011-05-27 | 2024-03-20 | Glaxo Group Limited | Antigen binding proteins |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| CN104379179A (zh) * | 2012-04-11 | 2015-02-25 | 美国卫生和人力服务部 | 靶向b-细胞成熟抗原的嵌合抗原受体 |
| ES2829499T3 (es) | 2013-02-05 | 2021-06-01 | Engmab Sarl | Método para la selección de anticuerpos contra BCMA |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| EP3087101A4 (en) | 2013-12-20 | 2017-12-06 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3808410A1 (en) | 2013-12-20 | 2021-04-21 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| KR102584938B1 (ko) | 2014-12-12 | 2023-10-05 | 2세븐티 바이오, 인코포레이티드 | Bcma 키메릭 항원 수용체 |
-
2016
- 2016-08-03 US US15/747,385 patent/US10683369B2/en active Active
- 2016-08-03 LT LTEP16750150.1T patent/LT3331910T/lt unknown
- 2016-08-03 SI SI201630675T patent/SI3331910T1/sl unknown
- 2016-08-03 MX MX2018001398A patent/MX2018001398A/es active IP Right Grant
- 2016-08-03 ES ES16750150T patent/ES2777602T3/es active Active
- 2016-08-03 WO PCT/EP2016/068549 patent/WO2017021450A1/en active Application Filing
- 2016-08-03 NZ NZ739252A patent/NZ739252A/en unknown
- 2016-08-03 EP EP16750150.1A patent/EP3331910B1/en active Active
- 2016-08-03 PT PT167501501T patent/PT3331910T/pt unknown
- 2016-08-03 PL PL16750150T patent/PL3331910T3/pl unknown
- 2016-08-03 HU HUE16750150A patent/HUE048939T2/hu unknown
- 2016-08-03 DK DK16750150.1T patent/DK3331910T3/da active
- 2016-08-03 BR BR112018001955-0A patent/BR112018001955B1/pt active IP Right Grant
- 2016-08-03 CN CN201680054839.0A patent/CN108350073B/zh active Active
- 2016-08-03 EA EA202092435A patent/EA202092435A3/ru unknown
- 2016-08-03 EA EA201890441A patent/EA036975B1/ru not_active IP Right Cessation
- 2016-08-03 SG SG10202007177XA patent/SG10202007177XA/en unknown
- 2016-08-03 CA CA2992797A patent/CA2992797A1/en active Pending
- 2016-08-03 KR KR1020187005941A patent/KR20180042271A/ko not_active Application Discontinuation
- 2016-08-03 RS RS20200276A patent/RS60030B1/sr unknown
- 2016-08-03 EP EP19208343.4A patent/EP3670535A1/en active Pending
- 2016-08-03 JP JP2018526303A patent/JP6682632B2/ja active Active
- 2016-08-03 AU AU2016302881A patent/AU2016302881B2/en active Active
-
2018
- 2018-01-22 ZA ZA2018/00435A patent/ZA201800435B/en unknown
- 2018-01-30 IL IL257233A patent/IL257233B/en active IP Right Grant
- 2018-01-31 CL CL2018000281A patent/CL2018000281A1/es unknown
- 2018-02-01 SA SA518390854A patent/SA518390854B1/ar unknown
- 2018-02-01 MX MX2020009649A patent/MX2020009649A/es unknown
- 2018-02-02 EC ECIEPI20187905A patent/ECSP18007905A/es unknown
- 2018-02-02 CO CONC2018/0001149A patent/CO2018001149A2/es unknown
- 2018-07-03 HK HK18108543.5A patent/HK1249114A1/zh unknown
-
2020
- 2020-03-10 CY CY20201100212T patent/CY1122804T1/el unknown
- 2020-03-10 HR HRP20200390TT patent/HRP20200390T1/hr unknown
- 2020-03-17 US US16/821,895 patent/US20200283545A1/en not_active Abandoned
- 2020-03-25 JP JP2020054175A patent/JP6903188B2/ja active Active
- 2020-04-17 CL CL2020001048A patent/CL2020001048A1/es unknown
- 2020-10-28 CL CL2020002801A patent/CL2020002801A1/es unknown
-
2022
- 2022-11-21 US US18/057,566 patent/US20230322957A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3331910T1 (sl) | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) | |
| HRP20181802T1 (hr) | Protutijela koja vežu humani cd3 | |
| ZA201900353B (en) | Anti-pd-l1 antibodies | |
| HK1257164A1 (zh) | 新型抗pd-l1抗體 | |
| SG11202001368SA (en) | Antigen-binding proteins tatrgeting shared antigens | |
| IL262295A (en) | Antibodies against pd-l1 | |
| HK1246324A1 (zh) | 抗pd-l1抗體 | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| PL3512547T3 (pl) | Przeciwciała anty-pd-1 | |
| IL250566A0 (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| ZA201901865B (en) | Anti-pd-1 antibodies | |
| SG11201703292VA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
| GB201511196D0 (en) | Monoclonal antibodies |